News - Neurological

Filter

Current filters:

Neurological

Popular Filters

26 to 50 of 914 results

FDA delays approval of Biogen Idec’s MS drug Plegridy

FDA delays approval of Biogen Idec’s MS drug Plegridy

18-03-2014

The US Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for…

Biogen IdecBiotechnologyNeurologicalNorth AmericaPlegridyRegulationUSA

Australian regulator finds no definite melanoma link for natalizumab

Australian regulator finds no definite melanoma link for natalizumab

18-03-2014

Australia’s Therapeutic Goods Administration revealed today that it is monitoring reports of melanoma…

Asia-PacificAustraliaBiogen IdecBiotechnologyNatalizumabNeurologicalRegulationTysabri

GW Pharmaceuticals updates on cannabinoid pipeline

GW Pharmaceuticals updates on cannabinoid pipeline

17-03-2014

UK biopharma company GW Pharmaceuticals this morning provided an update on the company’s cannabinoid…

DiabetesepidiolexGW PharmaceuticalsGWP42004GWP42006NeurologicalPharmaceuticalResearchSativex

Lundbeck and Otsuka update on European launch of Abilify Maintena

Lundbeck and Otsuka update on European launch of Abilify Maintena

17-03-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical’s European subsidiary…

Abilify MaintenaEuropeLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Modest growth forecast for global migraine market to 2023

Modest growth forecast for global migraine market to 2023

13-03-2014

The global migraine treatment market value is expected to undergo a modest increase over the coming years,…

CoLucid PharmaceuticalsGloballamiditanMarkets & MarketingMerck & CoMK-1602NeurologicalNuPathePharmaceuticalTeva Pharmaceutical IndustriesZecuity

Mallinckrodt gains FDA approval for Xartemis XR

Mallinckrodt gains FDA approval for Xartemis XR

12-03-2014

The US Food and Drug Administration has approved Ireland-headquartered specially drugmaker Mallinckrodt’s…

DepomedMallinckrodtNeurologicalNorth AmericaPharmaceuticalRegulationUSAXartemis XR

Teva agrees $27.6 million settlement with US Justice Dept

Teva agrees $27.6 million settlement with US Justice Dept

12-03-2014

US subsidiaries of Israeli generics giant Teva Pharmaceutical Industries have agreed to pay the US government…

ClozapineFinancialGenericsIvaxLegalNeurologicalNorth AmericaTeva Pharmaceutical IndustriesUSA

Japan’s market for schizophrenia treatment to double by 2022

Japan’s market for schizophrenia treatment to double by 2022

12-03-2014

Japan’s schizophrenia treatment market value will undergo significant growth over the coming decade,…

Asia-PacificJapanMarkets & MarketingNeurologicalPharmaceutical

Lundbeck releases positive results from six-year Onfi study

Lundbeck releases positive results from six-year Onfi study

12-03-2014

Danish CNS drug specialist Lundbeck has published results from a long-term, open-label extension study…

DenmarkLundbeckNeurologicalOnfiPharmaceuticalResearch

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

11-03-2014

Finland-based Biotie Therapies (Nasdaq OMX: BTH1V), which is focused on neurodegenerative and psychiatric…

BiotechnologyBiotie TherapiesFinancialFinlandHealthcareNeurologicalNRL-1SYN120

FDA accepts Lundbeck NDA for IV carbamazepine

FDA accepts Lundbeck NDA for IV carbamazepine

10-03-2014

The US subsidiary of Danish CNS specialist Lundbeck says that the Food and Drug Administration has accepted…

CarbamazepineCarbellaFinancialLigand PharmaceuticalsLundbeckNeurologicalNorth AmericaPharmaceuticalRegulationUSA

Trophos announces top-line results in trial of olesoxime in spinal muscular atrophy

10-03-2014

French privately-owned biopharmaceutical firm Trophos has released top-line results from a pivotal clinical…

FranceNeurologicalolesoximePharmaceuticalResearchTrophos

US researchers report blood test that can predict Alzheimer’s

10-03-2014

A blood test that can accurately predict the onset of Alzheimer's disease has been reported by, US researchers.…

NeurologicalNorth AmericaPharmaceuticalResearchUSA

Highlights from the Pharmacovigilance Risk Assessment Committee meeting

Highlights from the Pharmacovigilance Risk Assessment Committee meeting

09-03-2014

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) gave recommendations…

diacereindomperidoneEuropeGastro-intestinalsNeurologicalPharmaceuticalRegulationzolpidem

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

05-03-2014

US biotech firm Biogen Idec and Japanese drugmaker Eisai have entered into a collaboration to develop…

BAN2401BIIB037Biogen IdecBiotechnologyE2609EisaiLicensingNeurologicalResearch

New data show Janssen’s Xeplion significantly delays time to relapse vs oral antipsychotic monotherapy

New data show Janssen’s Xeplion significantly delays time to relapse vs oral antipsychotic monotherapy

05-03-2014

Janssen Pharmaceutica, a European subsidiary of US health care giant Johnson & Johnson released positive…

Janssen PharmaceuticaJohnson & JohnsonNeurologicalPharmaceuticalResearchXeplion

Titan Pharma in general agreement with FDA on pathway for Probuphine

Titan Pharma in general agreement with FDA on pathway for Probuphine

04-03-2014

California, USA-based Titan Pharma and its partner, Braeburn Pharmaceuticals, have agreed in principle…

Braeburn PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalProbuphineRegulationResearchTitan PharmaceuticalsUSA

RedHill Biopharma and IntelGenx respond to CRL on rizatriptan

04-03-2014

Emerging Israeli biotech firm RedHill Biopharma, together with Canadian drug delivery specialist IntelGenx,…

BiotechnologyIntelGenxNeurologicalNorth AmericaRedHill BiopharmaRegulationUSA

Alexza’s partner Teva launches antipsychotic Adasuve in USA

Alexza’s partner Teva launches antipsychotic Adasuve in USA

04-03-2014

US drug developer Alexza Pharmaceuticals says that its marketing partner, Israel-based generic drugs…

AdasuveAlexza PharmaceuticalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical IndustriesUSA

Perrigo transfers ELND005 assets; buys OTC products

01-03-2014

Drugmaker Perrigo has entered into a series of agreements with existing collaboration partner, Transition…

ELND005Mergers & AcquisitionsNeurologicalPerrigoPharmaceuticalResearchTransition Therapeutics

US orphan status for GW Pharma’s Epidiolex in Lennox-Gastaut syndrome

28-02-2014

UK-based GW Pharmaceuticals says that the Food and Drug Administration has granted orphan drug designation…

epidiolexGW PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationUSA

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Iroko Pharma gains FDA approval for low-dose indomethacin drug Tivorbex

25-02-2014

US specialty drugmaker Iroko Pharmaceuticals has received approval from the US Food and Drug has approved…

Iroko PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationTivorbexUSA

26 to 50 of 914 results

Back to top